Virtual Cancer Cachexia Conference 2020
September 10-11, 2020

Virtual Program

All presentations will be recorded

All Times Correspond to US EAST COAST TIME ZONE

Thursday, September 10, 2020

Keynote Address
10:45 am	Introductions – Denis Guttridge, PhD Medical University of South Carolina, USA
Chairs: Denis Guttridge, PhD – Medical University of South Carolina, USA Teresa Zimmers, PhD – Indiana University, USA
11:00 am	Kenneth C.H. Fearon Keynote Lectureship Annemie Schols, PhD Maastricht University, Netherlands Optimizing tumor treatment by new insights in cancer cachexia. No time to waste
12:00 pm	Break
Panel Discussion: Where are we in designing the proper trial?
12:15 pm	Moderators: Marie Fallon, MD – University of Edinburgh, UK Barry Laird, PhD – University of Edinburgh, UK Participants: Thomas Jagoe, MD – McGill University, Canada Tora Solheim, MD – St. Olavs Hospital, Norway David Currow, MD – University of Technology, Australia
1:00 pm	Break
Clinical Advances in Assessments and Management in Cancer Cachexia
Chairs: Richard Skipworth, MD – University of Edinburgh, UK Simon Wing, MD – McGill University, Canada
1:15 pm	Richard Dunne, MD University of Rochester, USA Measurement selection in cachexia clinical trials: Are we missing the mark?
1:45 pm	Jose Garcia, MD, PhD University of Washington, USA Novel insights on body composition and physical function in patients with cancer cachexia
2:15 pm	Eric Roeland, MD Harvard University, USA The skinny on the inaugural ASCO cachexia guidelines

Back to top ...

Friday, September 11, 2020

Mechanisms of Skeletal Muscle/Organ Wasting
Chairs: Andrew Judge, PhD – University of Florida, USA Paola Costelli, PhD – University of Torino, Italy
10:00 am	Imed Gallouzi, PhD McGill University, Canada The iNOS/NO pathway drives mitochondrial dysfunction to promote cancer-induced muscle wasting
10:30 am	Norbert Perrimon, PhD Harvard Medical School, USA Insights on cachexia from a Drosophila model of organ wasting
11:00 am	Break
11:15 am	Daniel Marks, MD, PhD Oregon Health & Science University, USA Bystander brain injury in cancer cachexia
11:45 am	Danna Breen, PhD Pfizer, USA Growth differentiation factor 15 (GDF-15) is a key regulator of cancer cachexia
12:15 pm	Break
Next Generation Researchers in Cancer Cachexia
Chairs: Rishi Jain, MD – Fox Chase Cancer Center, USA Cynthia Stretch, PhD – University of Calgary, Canada
12:30 pm	Andrew D’Lugos, PhD – University of Florida, USA The role of complement in pancreatic cancer cachexia
12:45 pm	Erin Talbert, PhD – University of Iowa, USA Plasma ceramides as a sexually dimorphic biomarker of pancreatic cancer-induced cachexia
1:00 pm	Brian Hain, PhD – The Pennsylvania State University College of Medicine, USA Loss of REDD1 prevents chemotherapy-induced muscle atrophy and weakness in mice
1:15 pm	Estefanía Simoes Fernández – University of São Paulo, Brazil Neuronal morphology and neuroglia compromised in cancer cachexia: a post-mortem neuropathological study
1:30 pm	Joshua Huot, PhD – Indiana University School of Medicine, USA ACVR2B antagonism as a countermeasure to multi-organ perturbations in metastatic colorectal cancer cachexia
1:45 pm	Brandon VanderVeen, PhD – University of South Carolina, School of Medicine, USA The effects of chemotherapy on skeletal muscle immune cell infiltration and activation
2:00 pm	Break

Cancer Cachexia Biomarker Initiative and Advancing Therapeutics
Chairs: Michael Espey, PhD – National Institutes of Health, USA Helen Heymann, PhD – Foundation of National Institutes of Health, USA
2:15 pm	Tania Kamphaus, PhD Foundation of National Institutes of Heath, USA Introduction to FNIH and biomarker initiative
2:30 pm	Teresa A. Zimmers, PhD Indiana University, USA Markers of cachexia in oncology – Project overview
Cancer Cachexia Society and Future Conferences
Chairs: Marilia Seelaender, PhD – University of Sao Paulo, Brazil James Carson, PhD – University of Tennessee Health Science Center, USA
3:00 pm	Denis Guttridge, PhD Medical University of South Carolina, USA
3:30 pm	Closing Remarks

Back to top ...